MNK Stock Mallinckrodt plc - Complete Overview
Nyse / Pharmaceutical Products / Healthcare / MNK Stock
|Avg Daily Volume||3.12M|
MALLINCKRODT PLC (MNK) OVERVIEW
MNK stock is a pharmaceutical products company traded on Nyse. It is valued at 1.02B US dollars. There are 83.08M shares outstanding which Mallinckrodt plc issued to investors. Volatility of the stock is HIGH, and the daily volume is 60.75% stock on average. It brought investors a total return of -51.36% over the last 12 months. Mallinckrodt plc stock is relatively cheap. It's P/E ratio is below the market average.
Should Value Investors Consider Mallinckrodt (MNK) Stock?
Is Mallinckrodt (MNK) a great pick from the value investor's perspective right now? Read on to know more.
Mallinckrodt: The Cheapest Stock In Global Healthcare
Mallinckrodt is valued at a massive discount to its global comparable peers.At one point, shares traded below adjusted EBITDA and since then has rebounded over 40%.The company's controversial best sel
A Buvaya Failure Could Sting Insys
Clinical trial data may suggests INSY's Buvaya does not provide the efficacy and safety characteristics to garner FDA approval.A bet on INSY is likely a bet on its R&D pipeline. A miss on Buvaya could
Mallinckrodt: Appeals Court Rules Inomax Patent Invalid
A Federal Circuit Court ruled the majority of a patent for MNK's Inomax was invalid.It could pave the way for Praxair's generic Inomax.Inomax represents over 20% of MNK's revenue. Acthar and Inomax ar
Depomed Earnings Preview
DEPO reports quarterly earnings tomorrow.The company is distancing itself from Nucynta.It has an unproven business model and more than $600MM in debt at junk levels.If EBITDA turns lower then the rati
Here's Why Mallinckrodt PLC Rose as Much as 16.3% Today
The wild ride continues for investors.
|Price to Earnings||0.70||58.99||86.82||29.24|
|Price to Book Value||0.16||4.24||4.45||3.48|
|Price to Sales||0.34||3.40||4.04||3.26|
|Return on Equity||29.60%||14.07%||14.08%||15.51%|
|Return on Assets||11.40%||6.17%||6.88%||5.81%|